Navigation Links
Prostaglandin receptor key to atherosclerosis development
Date:12/15/2008

Atherosclerosis a disease that includes the buildup of fatty, cholesterol-laden lumps of cells inside the artery wall is the underlying cause of heart attacks and strokes.

A team of Vanderbilt University Medical Center investigators has now demonstrated that a receptor for prostaglandin-E2 plays a key role in the development of atherosclerosis. The findings, reported this month in Cell Metabolism, point to this receptor and its signaling pathways as molecular targets for modulating atherosclerosis development.

Atherosclerosis is widely accepted to be an inflammatory disease process, involving immune system cells called macrophages.

"The first visible lesion in atherosclerosis looking under a microscope is the accumulation of cholesterol in macrophages or foam cells," said MacRae Linton, M.D., professor of Medicine and Pharmacology and senior author of the current studies. Since a major product of activated macrophages is prostaglandin-E2 (an inflammation-related signaling molecule), Linton and colleagues reasoned that this compound may play an important role in atherosclerosis.

Mounting evidence supports roles for prostaglandins and their receptors in atherosclerosis, but only two prostacyclin and thromboxane-A2 have been considered in detail, he said.

Linton, first author Vladimir Babaev, M.D., Ph.D., co-senior author Sergio Fazio, M.D., Ph.D., and colleagues focused on two receptors for prostaglandin-E2, called EP2 and EP4, because they were known to be expressed by cells in human atherosclerotic plaques.

To study the roles of these receptors in atherosclerosis, the investigators performed a modified bone marrow transplant to develop mice in which the blood cells lacked either the EP2 or the EP4 receptor. They transplanted the blood-forming cells into mice missing the LDL receptor a widely used model for studies of atherosclerosis because these mice rapidly develop plaques when fed a high-fat diet.

The researchers found that the mice with macrophages lacking the EP4 receptor had a significant reduction in atherosclerosis compared to mice with the EP4 receptor. They also observed an increase in macrophage programmed cell death (apoptosis) in the atherosclerotic lesions of mice with EP4-deficient cells.

The team examined EP4 receptor signaling pathways and discovered that two pathways known to be involved in macrophage cell survival (PI3K/Akt and NF-kappaB pathways) had lower activity in the EP4-deficient mice, suggesting a mechanism for the increase in macrophage cell death.

"Our studies clearly show that prostaglandin-E2 plays an important role in atherosclerosis and in macrophage survival," Linton said. "Prostacyclin and thromboxane aren't the whole story."

The findings suggest the potential for modulating the development of atherosclerosis with inhibitors of prostaglandin-E2 synthesis, which are already being studied, and also by manipulating the EP receptors or their signaling pathways, Linton said.

The link between macrophage apoptosis and lesion development remains unclear, he said.

There have been some reports that increased macrophage apoptosis in early lesions reduces the lesion area, Linton said. Other studies have suggested that macrophage apoptosis creates a pro-inflammatory environment that promotes the development of more complex lesions. Still other reports speculate that macrophage cell death promotes plaque rupture, causing heart attacks and strokes.

If the latter is true, Linton said, the current studies could offer a mechanistic explanation for how the drug Vioxx increased heart attacks in patients. Vioxx, a selective inhibitor of the enzyme cyclooxygenase-2 (COX-2), was withdrawn from the market because of concern about an apparent increase in cardiovascular risk.

The current findings suggest that because COX-2 inhibition would reduce prostaglandin-E2 levels (COX enzymes perform the first step in the production of prostaglandins), it might increase macrophage apoptosis and promote plaque rupture.

Linton said his team plans to pursue studies aimed at understanding how macrophage apoptosis impacts more advanced atherosclerotic lesions in terms of their complexity and stability.


'/>"/>

Contact: Kathy Whitney
kathy.f.whitney@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
2. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
3. Low level of neuronal receptor linked to mild cognitive impairment and Alzheimers disease
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Food restriction increases dopamine receptor levels in obese rats
7. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
8. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
9. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
10. Receptor protein appears to be key in breakdown of kidney filtration
11. Cell-death receptor links cancer susceptibility and inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... The California State University Institute for Palliative Care ... interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing ... Diego on Sept. 28 and 29, 2017, on the campus of California State University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association ... marketing programs at the annual Building Better Radiology Marketing Programs conference, held ... in Fort Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
(Date:2/23/2017)... , February 23, 2017 Obese ... increasing caseload for varicose veins in their body. The ... are prompting the adoption of endovenous laser therapy for ... endovenous laser therapy market, published by Future ... lifestyle choices and consequences of obesity have collectively factored ...
Breaking Medicine Technology: